title: A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America.
abstract: The escalating role played by managed care organizations in the health-care system is reflected in the increased demand for cost-effectiveness analyses (CEAs) to assess the balance between economic impact and clinical efficacy. For example, the high incidence and costs associated with colorectal cancer in Latin America calls for a comprehensive economic evaluation to ensure appropriate allocation of limited health-care funds. In addition, the current call for a "societal" perspective of such analyses indicates the need for increased consideration of the concerns of both patient and health-care provider. The introduction of oral tegafur and uracil (UFT) provided the opportunity to evaluate the pharmacoeconomic advantage of the new agent compared with the standard fluorouracil (5-FU). Results of this study indicated an economic advantage for oral UFT vs a 5-FU-based regimen in the treatment of colorectal cancer in Brazil and Argentina. It was further noted that the mild toxicity profile of UFT reduced both the number of clinic visits and the need for venipuncture procedures. Noting that oral UFT may have a positive impact on quality of life in addition to its estimated economic benefit, it was concluded that prospective economic research and quality-of-life evaluations are needed to fully assess the pharmacoeconomic impact of oral UFT.
authors.affiliation: Hospital de Clinicas Belo Horizonte, Brazil.
authors.forename: A
authors.initials: A
authors.lastname: Murad
authors.forename: C A
authors.initials: CA
authors.lastname: de Andrade
authors.forename: C
authors.initials: C
authors.lastname: Delfino
authors.forename: S
authors.initials: S
authors.lastname: Arikian
authors.forename: J
authors.initials: J
authors.lastname: Doyle
authors.forename: N
authors.initials: N
authors.lastname: Sinha
mesh_terms: D001118:Argentina; D001938:Brazil; D017024:Chemotherapy, Adjuvant / Q000191:economics; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000191:economics*; D003365:Costs and Cost Analysis; D004338:Drug Combinations; D016527:Drug Costs; D005472:Fluorouracil / Q000008:administration & dosage / Q000191:economics; D006801:Humans; D009010:Monte Carlo Method; D013020:South America; D005641:Tegafur / Q000191:economics* / Q000627:therapeutic use; D014498:Uracil / Q000191:economics* / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil